ARTICLE | Clinical News
LJPC-501: Phase I/II started
September 15, 2014 7:00 AM UTC
La Jolla began an open-label, U.S. Phase I/II trial to evaluate 1-250 ng/kg/minute LJPC-501 given by continuous infusion for 5 days in up to 15 patients with Type 1 and/or Type 2 HRS. ...